Braftovi, Erbitux, and Mektovi: Analyzing Market Dynamics and Emerging Trends by 2032
Overview of the Braftovi + Erbitux ± Mektovi Combination Therapy The combination of Braftovi (encorafenib), Erbitux (cetuximab), and optionally Mektovi (binimetinib) has emerged as a pivotal treatment strategy for certain cancers, especially metastatic colorectal cancer (mCRC) harboring the BRAFV600E mutation. This targeted therapy works by inh